Skip to content

A Surgical Approach to the Management of Type II Diabetes Mellitus in Patients With a BMI Between 25-35 kg/m2

A Surgical Approach to the Management of Type II Diabetes Mellitus in Patients With a BMI Between 25-35 kg/m2

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01197963
Enrollment
3
Registered
2010-09-09
Start date
2010-09-30
Completion date
2014-02-28
Last updated
2015-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Keywords

Type 2 diabetes mellitus

Brief summary

The purpose of the study is to determine if by performing surgery we can cure Type II Diabetes. The surgical procedures: 1. a sleeve gastrectomy, cutting out a portion of the stomach, which provides restriction of caloric intake and rapid gastric emptying. 2. ileal transposition which involves repositioning a 150cm segment of the ileum into the jejunum causing improved glucose homeostasis.

Interventions

PROCEDURESleeve Gastrectomy and Ileal transposition

Laparoscopic sleeve gastrectomy with ileal transposition

DIETARY_SUPPLEMENTdietary and medical management

dietary and medical routine management patients are currently following with an endocrinologist.

Sponsors

The University of Texas Health Science Center, Houston
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* age- 21-55 years. * Body Mass Index between 25-35 kf/m2. * currently being treated for type 2 diabetes mellitus with oral hypoglycemic, insulin or both for the at least 3 years. * Documented HbA1c\>7.5% for at least 3 months. * Stable weight for 3 months (+/-) * Evidence of stable medical treatment for diabetes over the past 12 months. * Able to provide informed consent -Female subject agrees to participate in accepted birth control methods -

Exclusion criteria

* Type I diabetes/juvenile onset * C-Peptid levels below 1.0 ng/ml * Previous major upper abdominal surgery --Pregnant or plans to become pregnant with in the next 12 months * Current Malignancy * Severe pulmonary, cardia, or renal disease * Eating disorders such as bulimia or binge-eating * Severe mental health disorders such as schizophrenia and bipolar disorder * Obesity due to other metabolic disorders * taking appetite suppressants * currently abusing illicit drugs,alcohol or using tobacco products * Unable to provide informed consent * Unwillingness or unable to comply with study procedures * any condition that deems them unsuitable for the study in the opinion of the investigators

Design outcomes

Primary

MeasureTime frameDescription
Serial Postoperative HgA1c levels1 month intervals for 3 months then every 3 months there afterEffectiveness of the transposition to alleviate hyperglycemia will be measured by following serial post operative HbA1c levels. The change from baseline mearusements will be used to determine the outcome. Type 2 diabetes is considered resolved if there is normalization of fasting glucose(\<110 mg/dl) normal HbA1c (\<6%) and no need for diabetic medications.

Secondary

MeasureTime frameDescription
Serial Postoperative Lipid Profiles levels1 month for the first 3 months then every 3 months there afterLipid profiles will be examined at follow up witha goal of total cholesterol \<200 mg/dl, low-density lipoprotein (LDL) levels \<100 mg/dl, triglyceride levels \<150 mg/dl, and high-density lipoprotein (HDL) levels \>40 mg/dl. Patients will be fasting for 8 hours and the serum glucose and GLP-1 level will be checked.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026